Kidney cancer, version 2.2014

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 2, 2014, Pages 175-182

  Motzer, Robert J ^a   Jonasch, Eric ^b   Agarwal, Neeraj ^c   Beard, Clair ^d   Bhayani, Sam ^e   Bolger, Graeme B ^f   Chang, Sam S ^g   Choueiri, Toni K ^d   Derweesh, Ithaar H ^h   Gupta, Shilpa ⁱ   Hancock, Steven L ^j   Kim, Jenny J ^k   Kuzel, Timothy M ^l   Lam, Elaine T ^m   Lau, Clayton ⁿ   Levine, Ellis G ^o   Lin, Daniel W ^p   Margolin, Kim A ^p   Michaelson, M Dror ^q   Olencki, Thomas ^r   Pili, Roberto ^o   Plimack, Elizabeth R ^s   Rampersaud, Edward N ^t   Redman, Bruce G ^u   Ryan, Charles J ^v   Sheinfeld, Joel ^a   Sircar, Kanishka ^b   Somer, Brad ^w   Wang, Jue ^x   Wilder, Richard B ⁱ   Dwyer, Mary A ^y   Kumar, Rashmi ^y   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Dana Farber Brigham and Women's Cancer Center   (United States)

^e BARNES JEWISH HOSPITAL   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j STANFORD CANCER INSTITUTE   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m University of Colorado Cancer Center   (United States)

ⁿ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^o ROSWELL PARK CANCER INSTITUTE   (United States)

^p SEATTLE CANCER CARE ALLIANCE   (United States)

^q MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^r OHIO STATE UNIVERSITY   (United States)

^s FOX CHASE CANCER CENTER   (United States)

^t DUKE CANCER INSTITUTE   (United States)

^u UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^x NEBRASKA MEDICAL CENTER   (United States)

^y National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CLEAR CELL CARCINOMA; CLINICAL PRACTICE; CONTINUING EDUCATION; HUMAN; KIDNEY CANCER; PRACTICE GUIDELINE; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84895830277     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0018     Document Type: Review

References (51)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html. Accessed January 10, 2014.
3. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:37-42. (Pubitemid 34053336)
4. Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009;136:521-534.
5. Seeliger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26:611-621. (Pubitemid 350115107)
6. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484. (Pubitemid 43199434)
7. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281. (Pubitemid 46849157)
8. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202-209.
9. Venugopal B, Ansari J, Aitchison M, et al. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urol 2013;13:26.
10. Blank CU, Bono P, Larkin JMG, et al. Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: subgroup analysis of REACT [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 402.
11. Larkin JM, Fisher RA, Pickering LM, et al. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J Clin Oncol 2011;29:e241-242.
12. Koh Y, Kim JY, Lim HY, et al. Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 4544.
13. Escudier B, Bracarda S, Maroto J, et al. Open-label phase II trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis [abstract]. Presented at the European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract 2706.
14. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
15. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
16. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2011;77:163-171.
17. Sonpavde G, Hutson TE, Rini BI. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008;17:741-748. (Pubitemid 351843617)
18. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757-763.
19. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26:127-131.
20. Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012;62:1013-1019.
21. Ravaud A, Oudard S, Gravis-Mescam G, et al. First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP) [abstract]. J Clin Oncol 2009;27(Suppl):Abstract 5146.
22. Lee JL, Ahn JH, Lim HY, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012;23:2108-2114.
23. Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012;30:335-340.
24. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272-1280.
25. Beck J, Procopio G, Bajetta E, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011;22:1812-1823.
26. Unnithan J, Vaziri S, Wood DP Jr, et al. Characterization of type II papillary renal cell carcinoma and efficacy of sorafenib [abstract]. Presented at the 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, California. Abstract 409.
27. Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27:5788-5793.
28. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850. (Pubitemid 32119100)
29. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844. (Pubitemid 23132159)
30. Irshad T, Olencki T, Zynger DL, et al. Bevacizumab in metastatic papillary renal cell carcinoma (PRCC). ASCO Meeting Abstracts 2011;29:e15158.
31. Chowdhury S, Matrana MR, Tsang C, et al. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am 2011;25:853-869.
32. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763-2771. (Pubitemid 46179466)
33. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-624. (Pubitemid 36514472)
34. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004;28:435-441. (Pubitemid 38436516)
35. Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist 2012;17:46-54.
36. Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011;28:1530-1533.
37. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545-1551. (Pubitemid 39318900)
38. Haas N, Manola J, Pins M, et al. ECOG 8802: phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features [abstract]. Presented at the 2009 Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, Florida. Abstract 285.
39. Haas NB, Lin X, Manola J, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012;29:761-767.
40. Richey SL, Ng C, Lim ZD, et al. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2011;29:e203-205.
41. Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008;180:867-872; discussion 872.
42. Stadler WM, Halabi S, Ernstoff MS, et al. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol 2004;22(Suppl):Abstract 4515.
43. Meyer PN, Clark JI, Flanigan RC, Picken MM. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol 2007;128:70-79. (Pubitemid 47121717)
44. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010;116:5219-5225.
45. Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: the Bronx experience. Urology 2007;70:878-882. (Pubitemid 350192580)
46. Watanabe IC, Billis A, Guimaraes MS, et al. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol 2007;20:914-920. (Pubitemid 47267828)
47. Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol 2009;22(Suppl 2):S2-23.
48. Tokuda N, Naito S, Matsuzaki O, et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 2006;176:40-43; discussion 43.
49. Karakiewicz PI, Trinh QD, Rioux-Leclercq N, et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol 2007;52:1140-1145.
50. Gupta R, Billis A, Shah RB, et al. Carcinoma of the collecting ducts of bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 2012;36:1265-1278.
51. Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol 2007;177:1698-1702. (Pubitemid 46560664)